Carregant...
In silico insight into EGFR treatment in patients with lung carcinoma and T790M mutations
The T790M mutational basis of treatment failure, following treatment via alteration of the epidermal growth factor receptor (EGFR) pathway, is a well-known anomaly in patients with non-small cell lung cancer (NSCLC). The T790M mutation activates the kinase domain, causing tyrosine kinase inhibitors,...
Guardat en:
| Publicat a: | Exp Ther Med |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
D.A. Spandidos
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5443239/ https://ncbi.nlm.nih.gov/pubmed/28565760 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2017.4168 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|